N1-Methyl-Pseudo-UTP, GMP Grade, AOF

sodium salt, 100 mM, solution

A clean start in mRNA synthesis

Modified ribonucleotides enhance the expression and reduce the immunogenicity of mRNA. They are key to the success of therapeutic or vaccine mRNA.

Partially or completely replace UTP with this modified UTP to enhance the performance of modified mRNA. A fit-for-purpose reagent to manufacture mRNA for therapeutics and vaccines, Roche CustomBiotech N1-Methyl-Pseudo-UTP provides the performance, quality, and scale you need.


We have designed our manufacturing process from the master cell bank to final QC-release to exclude or minimize potential contaminants, thereby reducing overall process risk and simplifying procedures for regulatory approval.

Produced using validated manufacturing and cleaning processes up to the final filling step and released under stringent final QC checks. Know that you are getting consistent quality every time.

from the generation of the master cell bank to the final filling, noanimal-derived materials are used in the process. This greatly simplifies your risk analysis.

The enzymes used in the synthesis process have been made without the use of ß-lactam antibiotics. Therefore, allergic reactions to antibiotics is not a factor in your overall risk analysis.

tested during final QC-release for the absence of impurities such as nucleases, host-cell DNA and protein, bioburden, heavy metals, or endotoxins. Work with an enzyme at peak performance that poses no risk to downstream processing.

We work with you to provide the necessary technical documents for your regulatory submissions.

Changing reagent quality between pre-clinical development and commercialization poses a risk. Secure your processes by using the best available quality from the start.

Ordering Information

Technical documents

for certificates, method sheets (instructions for use), safety data sheets and software downloads
error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later